OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cortes on the Future of Ponatinib in CML Treatment

January 18th 2021

Jorge E. Cortes, MD, discusses the future of ponatinib in the treatment of patients with chronic myeloid leukemia.

Dr. Stiles on Treatment Advances Made in Early-Stage Lung Cancer

January 18th 2021

Brendon Stiles, MD, discusses the roles of surgery, radiation, and chemotherapy in treatment for early-stage lung cancer.

Dr. Hong on the Potential Clinical Implications of the SURPASS Trial in Gastric/GEJ Cancer

January 18th 2021

David S. Hong, MD, discusses the potential clinical implications of the phase 1 SURPASS trial in gastric/gastroesophageal junction cancer.

Dr. Rohs on the Role of Molecular Testing in Lung Cancer Management

January 18th 2021

Nicholas C. Rohs, MD, discusses the role of molecular testing in patients with lung cancer.

Dr. Harding on the Results of the SUMMIT Trial in HER2+ Biliary Tract Cancers

January 17th 2021

James J. Harding, MD, discusses the results of the ongoing, phase 2 SUMMIT basket trial in HER2-mutant advanced biliary tract cancers.

Dr. Zhu on the OS Results of the ClarIDHy Trial in IDH1+ Cholangiocarcinoma

January 17th 2021

Andrew Zhu, MD, PhD, discusses the final overall survival results from the phase 3 ClarIDHy trial in previously treated patients with IDH1-mutated cholangiocarcinoma.

Dr. Wainberg on the FIGHT Trial Results in FGFR2b+ Gastric/GEJ Cancer

January 16th 2021

Zev A. Wainberg, MD, of University of California, Los Angeles, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.

Dr. Subbiah on the Clinical Activity of Pralsetinib in RET+ Cholangiocarcinoma

January 16th 2021

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

Dr. Shitara on the FDA Approval of Trastuzumab Deruxtecan in HER2+ Metastatic Gastric/GEJ Cancer

January 15th 2021

Kohei Shitara, MD, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric/gastroesophageal junction cancer.

Dr. Fonseca Discusses Key Data in Multiple Myeloma

January 15th 2021

Rafael Fonseca, MD, discusses key data in multiple myeloma.

Dr. Kumar on Understanding the Safety Profiles of Combination Therapies in Multiple Myeloma

January 15th 2021

Shaji K. Kumar, MD, discusses the importance of understanding the safety profiles of combination therapies in multiple myeloma.

Dr. Ramalingam on the Potential of HER2 as a Driver Mutation in NSCLC

January 14th 2021

Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.

Dr. Tolaney on the Need to Develop Additional Biomarkers in mTNBC

January 14th 2021

Sara M. Tolaney, MD, MPH, discusses the need to develop additional biomarkers of response in metastatic triple-negative breast cancer.

Dr. Olin on the Rationale to Evaluate Menin Inhibitors in AML

January 14th 2021

Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.

Dr. Lees on the Utility of Genetic Testing in Ovarian Cancer

January 14th 2021

Brittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.

Dr. Kelly on the Safety Profile of Adjuvant Nivolumab in Resected Esophageal/GEJ Cancer

January 14th 2021

Ronan J. Kelly, MD, MBA, discusses the safety profile of adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.

Dr. Sun on the KEYNOTE-062 Design in Advanced Gastric/GEJ Cancer

January 14th 2021

Weijing Sun, MD, FACP, discusses the design of the KEYNOTE-062 trial in advanced gastric/gastroesophageal junction cancer.

Dr. Berlin on Unmet Needs in Pancreatic Cancer

January 14th 2021

Jordan D. Berlin, MD, discusses unmet needs in pancreatic cancer.

Dr. Ailawadhi on the Emergence of T-Cell Engagers in Multiple Myeloma

January 13th 2021

Sikander Ailawadhi, MD, discusses the emergence of T-cell engagers in multiple myeloma.

Dr. Mai on Barriers of Genetic Testing in CRC

January 13th 2021

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.